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Low-birth-weight individuals have a higher risk of
hypertension and end-stage renal disease (ESRD). Here we
investigated whether low birth weight was associated with
earlier onset of ESRD in patients with autosomal dominant
polycystic kidney disease (ADPKD). In collaboration with all
Danish departments of nephrology, 307 of 357 patients with
ADPKD and ESRD born and living in Denmark were recruited.
We were able to analyze complete data of 284 patients
obtained from both hospital medical files and midwife
protocols in the Danish State Archives. Multivariable linear
regression adjusted for birth weight, adult height, mean
arterial pressure, gender, birth decade, and type of
antihypertensive treatment showed that for every kilogram
increase in birth weight, the age at onset of ESRD significantly
increased by 1.7 years. Male gender and increased mean
arterial pressure were both associated with earlier onset of
ESRD. Patients treated with renin–angiotensin system
blockade or calcium channel blockers during follow-up had
significantly later onset of ESRD by 4.3 years and 2.1 years,
respectively. Treatment with beta-blockade or a diuretic
was not associated with the age at onset of ESRD. Thus, low
birth weight may contribute to considerable phenotypic
variability in the progression of renal disease between
individuals with ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD) is a
common genetic disease estimated to affect around 4–6 million
people worldwide.1 With the growth of renal cysts the renal
function gradually deteriorates, and 6% of all patients starting
renal replacement therapy in Denmark had ADPKD in the
year 2009.2 Mutations in the PKD1 gene are found in B85%
of the patients with ADPKD and these patients on average
reach end-stage renal disease (ESRD) about 20 years earlier
than the patients with mutations in the PKD2 gene (54.3 vs.
74.0 years).3,4 Despite adjustment for genotype and other
factors associated with severe progression in ADPKD, the often
considerable variability in renal disease progression found
within families with ADPKD is still largely unexplained.5
Nephrogenesis begins during the 9th week of gestation and
continues up through the 36th week where it ends, and the
number of nephrons is dependent on both gestational age and
growth conditions in utero.6 The Brenner hypothesis suggested
that intrauterine growth restriction results in low birth weight
(LBW), low nephron mass, and thereby an increased risk of
developing hypertension and renal disease.7 Today studies
have shown that LBW is associated with a reduced number
of enlarged glomeruli,8–10 salt sensitivity of blood pressure,
microalbuminuria, and low glomerular filtration rate.11–14
Further, children with minimal change nephropathy, nephrotic
syndrome or IgA nephropathy, and birth weights o2500 g
have an adverse renal outcome compared with normal birth
weight children.15–18 Two case–control studies and a large
cohort study have shown that individuals with birth weight
o2500 g have a 40–70% increased risk of developing ESRD
irrespective of gender and race.19–21
Whether LBW contributes to the renal disease variability
in individuals with ADPKD has, to our knowledge, never
been investigated. The primary objective of this study was
therefore to investigate whether LBW is associated with the
younger age at onset of ESRD in individuals with ADPKD.
Second, it was investigated whether other potential risk
factors influenced disease progression in ADPKD.
RESULTS
In a national collaboration with all Danish departments of
nephrology, 307 patients or 86% of the population with
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ADPKD and ESRD were included. Of these, 284 patients had
sufficient available data for the analyses. The year at onset of
ESRD ranged from 1970 to 2008 with a median of 2002. Each
patient was registered from first documented hospital contact
to the onset of ESRD with an average follow-up period of 4.8
years, and the clinical characteristics are outlined in Table 1.
Females were followed for a longer time period before the
onset of ESRD compared with males (5.5 years vs. 4.2 years;
P¼ 0.03). In the unadjusted analysis (Table 1), there were no
differences between males and females in the average age at
onset of ESRD, the percentage with hypertension, the mean
arterial pressure (MAP), or the percentage of patients on
either an ACE inhibitor or an angiotensin receptor blocker
(renin–angiotensin system (RAS) blockade). One or more
episodes of pyelonephritis was more often found in females
compared with males (34.6 vs. 15.8%; P¼ 0.0002). As
expected males were taller than females (Po0.0001) and a
higher percentage of males had a self-reported use of tobacco
(P¼ 0.0002; Table 1).
On the basis of a questionnaire answered by each patient,
information on birth weight was found in 95% of all patients
in the midwife protocols stored in the Danish State Archives.
Male babies had on average a larger birth weight compared
with female babies (3606 vs. 3458 g; P¼ 0.04). Of the 284
patients with a reported birth weight, 73 had an affected
father, 81 had an affected mother, and in the remaining 130
patients the parental affection status was unknown. In the
154 individuals where the affected parent had been reported
there were no difference in the average birth weight between
patients with an affected father vs. mother (3561 vs. 3494 g;
P¼ 0.49).
The unadjusted associations between birth weight and age
at onset of ESRD are outlined for women in Figure 1 and
men in Figure 2 with ADPKD. The regression lines show how
the age at onset of ESRD increased by 5.0 years in the 132
women and 3.9 years in the 152 men by every kilogram
increase in birth weight. The two correlation coefficients were
r¼ 0.30 in Figure 1 (P¼ 0.0005) and r¼ 0.24 in Figure 2
(P¼ 0.004).
Information on ethnicity, proteinuria, and ADPKD
genotype was not available. However, the included patients
Table 1 | Clinical characteristics of study population
Both Men Women
No. of patients 284 152 132
Follow-up (year), median (IQR) 4.8 (1.9–8.6) 4.2 (1.5–7.4) 5.5 (2.4–10.2)
Age at ESRD (year), mean (s.d.) 54.1(9.9) 53.4 (10.3) 54.9 (9.3)
Hypertensive (%) 262 (94.9) 140 (94.6) 122 (95.3)
MAP, mean (s.d.) 108.4 (8.9) 109.4 (9.5) 107.5 (8.0)
Users of RAS blockade (%) 69.0 71.1 66.7
Users of beta-blockade (%) 58.4 62.5 53.5
Users of calcium channel blockers (%) 68.0 74.3 60.5
Users of diuretics (%) 80.4 79.6 81.4
No antihypertensive treatment (%) 5.7 6.6 4.7
Potential risk factors
Pyelonephritis (%) 24.6 15.8 34.6
Smoking (%) 50.0 60.6 37.9
Birth weight (kg), mean (s.d.) 3.537 (594) 3.606 (624) 3.458 (550)
Distribution of birth weights
o2500 g, No. of patients (%) 9 (3.2) 4 (2.6) 5 (3.8)
2500–2999 g, No. of patients (%) 31 (10.9) 16 (10.5) 15 (11.3)
3000–3499 g, No. of patients (%) 81 (28.4) 40 (30.1) 41 (27.0)
3500–3999 g, No. of patients (%) 99 (34.7) 45 (29.6) 54 (40.6)
X4000 g, No. of patients (%) 65 (22.8) 46 (30.3) 19 (14.3)
Abbreviations: ESRD, end-stage renal disease; IQR, interquartile range; MAP, mean arterial pressure; RAS, renin–angiotensin system.
Follow-up is from first hospital contact documented in the medical records to onset of ESRD. Hypertensive patients had either a mean arterial pressure4107 mm Hg (blood
pressure 140/90) or used an antihypertensive drug during follow-up. Patients on RAS blockade used either an angiotensin-converting enzyme inhibitor or an angiotensin
receptor blocker.
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Figure 1 |Correlation between birth weight and age at onset
of end-stage renal disease (ESRD) in 132 Danish women with
autosomal dominant polycystic kidney disease. With every
kilogram increase in birth weight, the age at onset of ESRD
increased by 5.0 years, r¼ 0.30 and P¼ 0.0005 (unadjusted
analysis).
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were most likely Caucasians as all had been born in Denmark,
where o3% of the population were immigrants from Africa
or Asia in 2010.22 Self-reported smoking or ex-smoking and
episodes with pyelonephritis were not associated with the age
at onset of ESRD (data not shown). Instead the multivariable
linear regression analysis was adjusted for birth weight, MAP,
gender, birth decade, and type of antihypertensive treatment,
and the results are shown in Table 2. In this analysis every
kilogram increase in birth weight was associated with an
increase in age at onset of ESRD by 1.7 years (95%CI 0.5–2.9;
P¼ 0.006). Women had a 1.8-year later onset of ESRD
compared with men (95%CI 0.3–3.2; P¼ 0.02) and by every
mm Hg increase in the average MAP patients reached ESRD
0.1 year earlier (95%CI 0.2 to 0.07; P¼ 0.0005).
Treatment with RAS blockade or calcium channel blockers
during the follow-up was associated with 4.3 (95%CI 2.6–6.0;
Po0.0001) and 2.1 years (95%CI 0.5–3.7; P¼ 0.01) later
onset of ESRD, respectively. However, antihypertensive
treatments with beta-blockade or a diuretic was not
significantly associated with the age at onset of ESRD.
DISCUSSION
This study demonstrates that LBW was associated with an
earlier onset of ESRD in the Danish patients with ADPKD
and ESRD. Further, female gender and lower MAP, as well as
treatment with RAS blockade or calcium channel blockers
were all associated with a later onset of ESRD. A total of 307
patients or 86% of the population living with ADPKD and
ESRD in Denmark were recruited for this study. Major
strengths of our study are the number of included patients,
the complete registration of variables, as well as a clinically
relevant endpoint. Patients with ADPKD and ESRD were
recruited, as they share the etiology for renal disease and
comprise a large well-characterized population. The main
limitation of the study is the retrospective cross-sectional
design that may have resulted in a selected population. The
Danish National Registry on Dialysis and Transplantation
(NRDT) has complete registrations on all patients with ESRD
and ADPKD as all patients are treated by the same public
healthcare system. However, patients with ADPKD dying
before the onset of ESRD or living without having reached
ESRD are not registered and therefore are not included in
this study. Whether this has over- or underestimated the
influence of birth weight is difficult to say because the
prevalence of patients with ADPKD living and dying without
ESRD is uncertain. Patient data were also unavailable before
first hospital contact and this may have underestimated the
influence of hypertension which is a common finding in
young individuals with ADPKD.23 Data on the ADPKD
genotype, the level of proteinuria, as well as the growth in
number and volume of renal cysts were not available from the
hospital medical files, but adjustment for these important
risk factors would have strengthened the analysis. On the
basis of the midwife protocols, it was not possible to
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Figure 2 |Correlation between birth weight and age at onset
of end-stage renal disease (ESRD) in 152 Danish men with
autosomal dominant polycystic kidney disease. With every
kilogram increase in birth weight, the age at onset of ESRD
increased by 3.9 years, r¼ 0.24 and P¼ 0.004 (unadjusted
analysis).
Table 2 |Multivariable linear regression analysis of factors
associated with age at onset of end-stage renal disease in
284 patients with autosomal dominant polycystic kidney
disease
Adjusted variables
Change in age at ESRD
(year) estimate (95% CI) P-value
Birth weight (kg) 1.7 (0.5–2.9) 0.006
MAP (mm Hg) 0.1 (0.2 –0.07) 0.0005
Gender
Male (reference) — —
Female 1.8 (0.3–3.2) 0.02
RAS blockade
No (reference) — —
Yes 4.3 (2.6–6.0) o0.0001
Beta-blockade
No (reference) —
Yes 1.5 (0.03–3.0) 0.05
Calcium channel blockade
No (reference) —
Yes 2.1 (0.5–3.7) 0.01
Diuretic
No (reference) —
Yes 0.3 (1.7–2.3) 0.8
Birth decade
1921–1930 33.3 (21.1–45.5) o0.0001
1931–1940 25.7 (14.0–37.5) o0.0001
1941–1950 16.4 (4.7–28.2) 0.006
1951–1960 9.3 (2.5–21.1) 0.1
1961–1970 1.1 (13.1–10.9) 0.9
1971–1980 (reference) — —
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; MAP, mean
arterial pressure; RAS, renin–angiotensin system.
Positive estimates denote older age at onset of ESRD in years per variable (unit) and
negative estimates denote younger age at ESRD per variable (unit). Patients on RAS
blockade had used either an angiotensin-converting enzyme inhibitor or an
angiotensin receptor blocker during follow-up.
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determine the gestational age. However, Vikse et al.21
reported that birth weight alone seemed a better predictor
of ESRD than birth weight adjusted for gestational age.
Despite the limitations of this study, the design is robust and
the results are reliable.
LBW is a well-documented marker of nephron number
endowment,8–10 and LBW has been associated with later
onset of hypertension and chronic kidney disease.12,24 In
patients with Type 2 diabetes, IgA nephropathy, minimal
change nephropathy, or nephrotic syndrome LBW is
associated with an unfavorable renal outcome compared
with patients with normal birth weights.15–18,25 A large study
from Norway followed a birth cohort for 38 years and
demonstrated that birth weightso2500 g was associated with
a relative risk of 1.7 for developing ESRD.21 Similar findings
have been reported by two case–control studies demonstrat-
ing a 40–60% higher risk of developing ESRD in individuals
with a birth weight o2500 g, irrespective of gender and
race.19,20 In the present study and after adjustment for
variations in MAP, every kilogram increase in birth weight
was associated with a 1.7-year later onset of ESRD. This result
suggests that LBW in itself predisposes to an earlier onset of
ESRD in patients with ADPKD, and this is consistent with
previous studies as well as the hyperfiltration theory
proposed by Brenner et al.26
Between 1990 to 2007, Danish males with ADPKD had a
higher risk of developing ESRD compared with females, and
gender was therefore included as a risk factor in the
multivariable analysis.27 That women had a 1.8-year later
onset of ESRD compared with men in the multivariable
regression analysis is therefore in agreement with previous
studies from the United States, Europe, and Japan.28–30
Hypertension is associated with severe renal disease pro-
gression in ADPKD, and MAP is a well-established measure
of hypertension. MAP combines both systolic blood pressure
(SBP) and diastolic blood pressure (DBP) registrations,
where a blood pressure of 140/90 mm Hg is equivalent of
a MAP of 107 mm Hg. To our knowledge, the number of
antihypertensive medications does not influence progression
in ADPKD as long as the blood pressure is well treated, and
therefore MAP was included in the multivariable linear
regression analysis. Although both men and women had
received an almost adequate antihypertensive drug therapy
with an average MAP close to 107 mm Hg during the follow-
up period (Table 1), an elevated MAP was still significantly
associated with younger age at ESRD.
Studies have shown that the renin–angiotensin system is
upregulated in the human kidneys with ADPKD.31,32 RAS
blockade was included in the multivariable analysis, as the
treatment with ACE inhibitors have been shown to
significantly reduce proteinuria, optimize the treatment of
hypertension, and halt the increase in LVMI in patients with
ADPKD.33–35 Further studies have demonstrated that the
intrarenal renin–angiotensin system is upregulated by 4 weeks
of age in LBW rat offspring compared with controls.36
Inhibition of the renin–angiotensin system may therefore
have additional benefits in LBW individuals with ADPKD. In
the present study the use of RAS blockade was not only
associated with a 4.3-years later onset of ESRD (Table 2), but
also treatment with calcium channel blockers was signifi-
cantly associated with later onset of ESRD. Patients with
ADPKD often experience a rapid decline in renal function
when approaching ESRD, where treatment with RAS
blockade is perhaps less likely to be used or discontinued,
and as these results were not adjusted for the duration
of treatment with RAS blockade or calcium channel
blockers, these results should be interpreted cautiously.
Whether inhibition of the renin–angiotensin system
slows renal progression in ADPKD awaits the ongoing
HALT-PKD trial.37
Despite adjustment for established risk factors, the often
considerable variability in renal disease progression found
within families with ADPKD is largely unexplained.5,38,39
Results from the present study suggest that variations in birth
weight and the antihypertensive treatment may help explain a
larger degree of the variability in renal progression found
within the ADPKD families.
In summary, this nationwide retrospective cross-sectional
study is the first to demonstrate that birth weight is an
important factor that may influence the age at onset of ESRD
in ADPKD.
Every kilogram increase in birth weight was associated
with a 1.7-year later onset of ESRD. Female gender, lower
MAP, and treatment with RAS blockade or calcium channel
blockers were all associated with the later onset of ESRD.
Together these factors may contribute to the considerable
phenotypic variability found within families with ADPKD.
MATERIALS AND METHODS
Data collection
In order to identify the midwife protocols in the Danish State
Archives, the names of both the parents as well as the place and date
of birth are required. Therefore, all included individuals gave their
written informed consent and answered a questionnarie allowing the
following variables to be recorded: name of both parents, place
and date of birth, use of tobacco, and affected family members.
In the Danish State Archives, midwife protocols were available since
the year 1927. Midwife protocols were photographed to confirm the
name of parents, date and birth place as well as the birth weight on
each patient. Clinical data were registered from hospital medical files
once every year until creatinine was above the reference value and
thereafter four times every year until the patient reached ESRD. The
following variables were registered: SBP and DBP blood pressure
measurements, number and type of antihypertensive medications,
patient height (first available registration), episodes of pyelone-
phritis, and age at onset of ESRD defined as first day of treatment
with dialysis or the date of first renal transplantation before dialysis.
MAP was calculated as MAP¼ 1/3(SBP)þ 2/3(DBP). Hypertensive
patients mentioned in Table 1 had either a mean MAP
4107 mm Hg or used an antihypertensive drug during follow-up.
If an individual had used either an ACE inhibitor or an angiotensin
receptor blocker they were classified as on RAS blockade. Smoking
status was registered on the basis of a questionnaire filled out by
the patients, and the group of smokers included also ex-smokers.
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This study was approved by the Danish Data Protection Agency with
reference number 2007-41-1012.
Study population
The NRDT contains data on all patients actively treated for ESRD.
On the basis of ICD-10 code DQ61.2 (WHO International
Classification of Diseases 10th revision) all the patients with
ADPKD and ESRD living in Denmark between 1 January 2007
and 31 December 2008 were identified. A total of 359 patients born
in Denmark after 1 January 1927 were asked to participate, of which
307 patients (86%) participated by answering a questionnaire. On
the basis of hospital medical files nine patients were excluded. Four
did not have ADPKD according to the diagnostic ultrasonographic
criteria proposed by Pei et al.40 and another four had been
nephrectomized before the onset of ESRD. The last patient was an
extreme outlier (ESRD age 15 years, birth weight 2900 g) and was
therefore excluded from the statistical analyses. The midwife
protocol could not be found in 14 cases and this left a total of
284 patients or 95% of the included patients for the analyses. Of the
284 patients, 2 unrelated patients were from twin births. One had
a birth weight of 3000 g (age 44 years at ESRD) and the second
weighed 3150 g (age 50 years at ESRD). Family relations are
undetermined as these were not registered.
Statistical analyses
The mean follow-up period in males and females was compared
using the Wilcoxon Two-Sample Test. Differences between genders
regarding ESRD age, average MAP, adult height, and birth weight
were analyzed by a two-sample t-test. A chi-square test was used to
compare the percentage of hypertensives, patients on RAS blockade,
patients with pyelonephritis and smokers in males and females.
Multivariable linear regression was used to analyze how the age at
onset of ESRD was affected by birth weight, MAP, gender, birth
decade, and the type of antihypertensive treatment as well as
smoking and pyelonephritis. Birth decade was included in the
multivariable model to adjust for the improved prognosis seen in
patients with ADPKD.27
With age at ESRD as outcome, an interaction between birth
weight and the other significant predictors was analyzed (data not
shown). Only birth decade showed a significant interaction with
birth weight, and although the age at ESRD increased with birth
weight for all decades, this effect was stronger in the earlier birth
decades. This might be explained by smaller sample sizes in the later
birth decades. Smoking and pyelonephritis were not associated with
the age at ESRD and were therefore not in the analysis shown in
Table 2. P-values o0.05 were considered significant. The statistical
analyses and graphics were made using SAS 9.1 software (SAS
Institute, Cary, NC).
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